Dishman Carbogen Amcis Limited Stock Price Today (NSE: DCAL)
Fundamental Score
Dishman Carbogen Amcis Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Dishman Carbogen Amcis Limited share price today is ₹145.02, down 2.94% on NSE/BSE as of 30 October 2026. Dishman Carbogen Amcis Limited (DCAL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.27K (Cr). The 52-week high for DCAL share price is ₹303.00 and the 52-week low is ₹128.50. At a P/E ratio of 140.80x, DCAL is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 1.56% and a debt-to-equity ratio of 0.42.
Dishman Carbogen Amcis Limited Share Price Chart — NSE/BSE Historical Performance
Dishman Carbogen Amcis Limited share price chart: -7.56% return over the past month. 52-week high ₹303.00, 52-week low ₹128.50.
Dishman Carbogen Amcis Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹149.42 | ₹150.02 | ₹144.05 | ₹145.02 | 84.11K (Cr) | |
| ₹148.99 | ₹153.15 | ₹146.76 | ₹149.42 | 1.13L (Cr) | |
| ₹147.70 | ₹150.85 | ₹146.02 | ₹148.86 | 99.15K (Cr) | |
| ₹138.84 | ₹149.65 | ₹138.60 | ₹147.70 | 1.99L (Cr) | |
| ₹137.24 | ₹142.01 | ₹135.65 | ₹138.84 | 2.23L (Cr) | |
| ₹140.40 | ₹140.56 | ₹133.71 | ₹136.28 | 1.33L (Cr) | |
| ₹142.10 | ₹144.88 | ₹138.41 | ₹140.02 | 1.95L (Cr) | |
| ₹145.80 | ₹146.39 | ₹140.41 | ₹142.10 | 1.81L (Cr) | |
| ₹150.00 | ₹150.84 | ₹145.20 | ₹145.80 | 89.60K (Cr) | |
| ₹151.50 | ₹151.50 | ₹148.81 | ₹149.83 | 86.11K (Cr) |
Dishman Carbogen Amcis Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹156.96 | ₹157.55 | ₹133.71 | ₹145.02 | -7.61% | |
| ₹179.09 | ₹188.00 | ₹156.35 | ₹157.47 | -12.07% | |
| ₹187.30 | ₹201.00 | ₹167.31 | ₹178.34 | -4.78% | |
| ₹176.00 | ₹204.50 | ₹175.00 | ₹186.94 | +6.22% | |
| ₹195.65 | ₹202.00 | ₹167.25 | ₹175.37 | -10.37% | |
| ₹184.80 | ₹224.40 | ₹173.80 | ₹194.70 | +5.36% | |
| ₹136.73 | ₹192.20 | ₹132.20 | ₹183.18 | +33.97% | |
| ₹169.33 | ₹177.58 | ₹128.50 | ₹129.97 | -23.24% | |
| ₹214.78 | ₹233.85 | ₹173.50 | ₹175.06 | -18.49% | |
| ₹248.80 | ₹267.00 | ₹200.35 | ₹218.47 | -12.19% | |
| ₹240.65 | ₹274.30 | ₹211.55 | ₹247.59 | +2.88% | |
| ₹292.00 | ₹302.90 | ₹228.00 | ₹239.20 | -18.08% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Dishman Carbogen Amcis Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Dishman Carbogen Amcis Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DCAL across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (15.47%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Excellent EPS Growth (20.89% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (20.89% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (59.32%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (1.56%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.16%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 140.80x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-347.24%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Interest Coverage (1.60x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-2.56 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 6.04%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Dishman Carbogen Amcis Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Dishman Carbogen Amcis Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
29.8/100 | ₹145.02₹145 | ₹2273.91₹2273.91 | 140.80Average 140.8 Average | 1.56%Poor 1.56% Poor | 3.16%Poor 3.16% Poor | 0.42Excellent 0.4 Excellent | 20.89%Excellent 20.89% Excellent | 8.93%Good 8.93% Good | 0.00% | |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 72.9/100 | ₹1758.80₹1759 | ₹421988.88₹421988.88 | 34.90Average 34.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 67.2/100 | ₹9144.50₹9145 | ₹242329.25₹242329.25 | 82.97Average 83.0 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 54.8/100 | ₹4558.90₹4559 | ₹154300.53₹154300.53 | 72.83Average 72.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 71.6/100 | ₹1123.00₹1123 | ₹112075.40₹112075.40 | 25.03Average 25.0 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 53.5/100 | ₹2060.10₹2060 | ₹111296.90₹111296.90 | 101.68Average 101.7 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 35.2/100 | ₹1325.10₹1325 | ₹107048.20₹107048.20 | 31.75Average 31.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 36.5/100 | ₹1233.00₹1233 | ₹102955.50₹102955.50 | 31.87Average 31.9 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1666.90₹1667 | ₹95913.43₹95913.43 | 26.05Average 26.0 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 59.7/100 | ₹2275.50₹2276 | ₹93978.15₹93978.15 | 45.98Average 46.0 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 77.1/100 | ₹1961.60₹1962 | ₹89694.16₹89694.16 | 16.21Average 16.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price421988.88 Cr
- Divi's Laboratories Limited share price242329.25 Cr
- Torrent Pharmaceuticals Limited share price154300.53 Cr
- Zydus Lifesciences Limited share price112075.40 Cr
- Laurus Labs Limited share price111296.90 Cr
Dishman Carbogen Amcis Limited PE Ratio History
Historical price-to-earnings ratio for DCAL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.21 | ₹247.59 | 1179x |
| FY 2022 | ₹1.15 | ₹94.90 | 82.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Dishman Carbogen Amcis Limited Quarterly Performance
Latest quarterly metrics for DCAL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-4.29%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-347.24%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
8.93%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
20.89%
Compounded annual net profit growth over 5 years
Dishman Carbogen Amcis Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for DCAL — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Dishman Carbogen Amcis Limited Financial Statements
Annual income statement, balance sheet and cash flow for Dishman Carbogen Amcis Limited (DCAL) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Dishman Carbogen Amcis Limited
About DCAL (Dishman Carbogen Amcis Limited)
D vitamins; and specialty chemicals, as well as provides services for early and late-stage contract research and manufacturing, and high-potency APIs. Dishman Carbogen Amcis Ltd i...s a globally recognized pharmaceutical company specializing in contract development and manufacturing organization (CDMO) services. With a strong emphasis on innovation and quality, DCAL provides comprehensive solutions to pharmaceutical and biotechnology companies from early-stage research to commercial manufacturing. The company's state-of-the-art facilities and experienced team of scientists and engineers offer a wide range of services including custom synthesis, process development, scale-up, analytical testing, and formulation development. DCAL is committed to meeting the evolving needs of its clients by delivering high-quality products and services in a timely and cost-effective manner. DCAL operates with a focus on advanced technologies and complex chemistries, enabling the development and manufacturing of specialized pharmaceutical products. The company excels in handling challenging molecules, including highly potent APIs (HPAPIs) and controlled substances, while maintaining the highest standards of safety and regulatory compliance. DCAL's expertise extends to various therapeutic areas, including oncology, neurology, and infectious diseases, and the company is dedicated to supporting its clients in bringing innovative medicines to market. Through its commitment to excellence, DCAL has established itself as a trusted partner for pharmaceutical companies worldwide. With a global footprint and a customer-centric approach, Dishman Carbogen Amcis Ltd strives to build long-lasting partnerships with its clients. The company's integrated services and collaborative approach ensure seamless project execution and efficient delivery of results. DCAL's commitment to sustainability and environmental responsibility further underscores its dedication to ethical business practices. By combining cutting-edge technology, scientific expertise, and a strong commitment to customer satisfaction, Dishman Carbogen Amcis Ltd continues to drive innovation and growth in the pharmaceutical industry.
Company Details
Key Leadership
DCAL Share Price: Frequently Asked Questions
What is the current share price of Dishman Carbogen Amcis Limited?
Dishman Carbogen Amcis Limited (DCAL) trades at ₹145.02 on NSE and BSE. Market cap ₹2.27K (Cr). Educational data only.
What is the P/E ratio of Dishman Carbogen Amcis Limited?
Dishman Carbogen Amcis Limited has a P/E of 140.80x vs industry average 34.89x.
What is the Bull Run score for Dishman Carbogen Amcis Limited?
Dishman Carbogen Amcis Limited has a Bull Run score of 29.8/100 based on 25+ financial parameters.
Does Dishman Carbogen Amcis Limited pay dividends?
Dishman Carbogen Amcis Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Dishman Carbogen Amcis Limited?
Dishman Carbogen Amcis Limited has ROE of 1.56%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Dishman Carbogen Amcis Limited?
Dishman Carbogen Amcis Limited has debt-to-equity of 0.42.
Is Dishman Carbogen Amcis Limited a good investment?
Bull Run gives Dishman Carbogen Amcis Limited a score of 29.8/100. This is not investment advice — consult a SEBI-registered advisor.